Insmed Inc (INSM)vsLipocine Inc (LPCN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
LPCN
Lipocine Inc
$7.36
+0.68%
HEALTHCARE · Cap: $53.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 30579% more annual revenue ($606.42M vs $1.98M). LPCN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
LPCN
Avoid17
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -54.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : LPCN
LPCN has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : LPCN
The primary concerns for LPCN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while LPCN is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
LPCN generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Lipocine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?